Free Trial

Growth Stocks To Watch Now - April 19th

Prologis logo with Finance background
Image from MarketBeat Media, LLC.

Key Points

  • MarketBeat's screener highlights five Growth stocks to watch: Prologis (PLD), Teledyne Technologies (TDY), Ascendis Pharma (ASND), Hamilton Lane (HLNE), and Tyra Biosciences (TYRA).
  • These names were picked because they had the highest dollar trading volume among Growth stocks in recent days; Growth stocks are expected to grow faster than the market but often carry higher valuations and greater price volatility.
  • Prologis stands out as a global logistics real estate leader with roughly 1.2 billion sq ft across 19 countries, and its Q1 2026 update indicates data centers are a key growth driver.
  • Five stocks to consider instead of Prologis.

Prologis, Teledyne Technologies, Ascendis Pharma A/S, Hamilton Lane, and Tyra Biosciences are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to grow revenue and earnings faster than the overall market, often due to competitive advantages, new products, or expanding markets. Investors buy them primarily for capital appreciation rather than income, since these firms typically reinvest profits instead of paying dividends. Because future growth is already priced in, growth stocks often carry higher valuations and greater price volatility. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Prologis (PLD)

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.

Read Our Latest Research Report on PLD

Teledyne Technologies (TDY)

Teledyne Technologies Incorporated, together with its subsidiaries, provides enabling technologies for industrial growth markets in the United States and internationally. Its Digital Imaging segment provides visible spectrum sensors and digital cameras; and infrared, ultraviolet, visible, and X-ray spectra; as well as micro electromechanical systems and semiconductors, including analog-to-digital and digital-to-analog converters.

Read Our Latest Research Report on TDY

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Read Our Latest Research Report on ASND

Hamilton Lane (HLNE)

Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.

Read Our Latest Research Report on HLNE

Tyra Biosciences (TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Read Our Latest Research Report on TYRA

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prologis Right Now?

Before you consider Prologis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prologis wasn't on the list.

While Prologis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines